Biologic Therapeutics. For everyone, everywhere

At Elysian Bio, we're highly committed to the mission of making biologic therapeutics accessible for everyone, everywhere.

Backed by the joint infrastructure of Grupo TRACSA (over 4,200 employees and multinational presence in LATAM) and Saya Bio (investors in funds like RA Capital, Perceptive Advisors, etc.), we're building the infrastructure and partnerships to launch high-quality biosimilar drug products to accelerate the Latin American market’s growth for this class of drugs.

Addressing the Unmet Medical Need

Nearly 200,000 cancer cases are diagnosed every year in Mexico but, despite the growing number of biologic therapeutic options available around the world.

Up to 70% of cancer patients

Our goal is to make that number equal 0 by 2035.

that could be eligible for these drugs, are given other, less-effective options.

Tapping into the Potential of the LATAM Market

We believe there is a massive untapped opportunity in Latin America for a specialized biopharma company that is fully focused on biosimilar monoclonal antibodies, that is capable of introducing and deploying high-quality, branded biosimilars in the region.